Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Tetra Therapeutics

https://tetratherapeutics.com/

Latest From Tetra Therapeutics

Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro

Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.

Deals Business Strategies

Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Antibody Development

Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.

Deals Coronavirus COVID-19

Shionogi Set To Acquire R&D Partner Tetra After Raising Stake

Japanese firm sets stage to acquire US bioventure after it raises stake just ahead of key readout for lead asset.

Neurology Deals

Shionogi Stays The Course As It Lays Out R&D Priorities

Japan's Shionogi lays out its R&D priorities, with a continued strategic focus on anti-infectives and CNS drugs, saying it is looking for the approval of four molecules in the coming year.

Research and Development Strategies Japan
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Tetra Discovery Partners LLC
UsernamePublicRestriction

Register